Neuregulin 1-ErbB4-PI3K signaling in schizophrenia and phosphoinositide 3-kinase-p110δ inhibition as a potential therapeutic strategy - PubMed (original) (raw)
Comparative Study
. 2012 Jul 24;109(30):12165-70.
doi: 10.1073/pnas.1206118109. Epub 2012 Jun 11.
Yanhong Wang, Yoshitatsu Sei, Patricio O'Donnell, Patrick Piantadosi, Francesco Papaleo, Richard E Straub, Wenwei Huang, Craig J Thomas, Radhakrishna Vakkalanka, Aaron D Besterman, Barbara K Lipska, Thomas M Hyde, Paul J Harrison, Joel E Kleinman, Daniel R Weinberger
Affiliations
- PMID: 22689948
- PMCID: PMC3409795
- DOI: 10.1073/pnas.1206118109
Comparative Study
Neuregulin 1-ErbB4-PI3K signaling in schizophrenia and phosphoinositide 3-kinase-p110δ inhibition as a potential therapeutic strategy
Amanda J Law et al. Proc Natl Acad Sci U S A. 2012.
Abstract
Neuregulin 1 (NRG1) and ErbB4, critical neurodevelopmental genes, are implicated in schizophrenia, but the mediating mechanisms are unknown. Here we identify a genetically regulated, pharmacologically targetable, risk pathway associated with schizophrenia and with ErbB4 genetic variation involving increased expression of a PI3K-linked ErbB4 receptor (CYT-1) and the phosphoinositide 3-kinase subunit, p110δ (PIK3CD). In human lymphoblasts, NRG1-mediated phosphatidyl-inositol,3,4,5 triphosphate [PI(3,4,5)P3] signaling is predicted by schizophrenia-associated ErbB4 genotype and PIK3CD levels and is impaired in patients with schizophrenia. In human brain, the same ErbB4 genotype again predicts increased PIK3CD expression. Pharmacological inhibition of p110δ using the small molecule inhibitor, IC87114, blocks the effects of amphetamine in a mouse pharmacological model of psychosis and reverses schizophrenia-related phenotypes in a rat neonatal ventral hippocampal lesion model. Consistent with these antipsychotic-like properties, IC87114 increases AKT phosphorylation in brains of treated mice, implicating a mechanism of action. Finally, in two family-based genetic studies, PIK3CD shows evidence of association with schizophrenia. Our data provide insight into a mechanism of ErbB4 association with schizophrenia; reveal a previously unidentified biological and disease link between NRG1-ErbB4, p110δ, and AKT; and suggest that p110δ is a previously undescribed therapeutic target for the treatment of psychiatric disorders.
Conflict of interest statement
The authors declare no conflict of interest.
Figures
Fig. 1.
(A) Increased expression of ErbB4 CYT-1 mRNA [*F(5, 50) = 3.81; P = 0.04] and decreased ErbB3 in patients with schizophrenia (n = 23) compared with normal control subjects (n = 32) [*F(1, 55) = 3.80; P = 0.045]. (B) Association between ErbB4 risk haplotype (AGG; rs7598440; rs839523; rs707284) and ErbB4 CYT-1 levels in the whole cohort [F(5, 50) = 4.00; P = 0.012] (AGG/AGG, n = 13; AGG/nonrisk, n = 28; nonrisk/nonrisk, n = 14). (C) Increased expression of PIK3CD (**β = 0.41; t = 3.20, P ≤ 0.002) and PIK3R3 (*β = 0.26; t = 1.97, P ≤ 0.025) in patients with schizophrenia (n = 23) compared with normal control subjects (n = 32). (D) PIK3CD expression in normal and patient-derived LCLs is associated with an ErbB4 risk haplotype (**β = −0.32; t = −2.57, P ≤ 0.01). (E and F) NRG1-stimulated intracellular [PI(3,4,5)P3] production is (E) reduced in schizophrenia (*β = −0.27; t = −1.89, P ≤ 0.032; n = 29 vs.19) and (F) associated with ErbB4 risk haplotype [*β = −0.41; t = −3.01, P ≤ 0.004; whole sample (AGG/AGG, n = 11; AGG/nonrisk, n = 23; nonrisk/nonrisk, n = 13)]. Values are mean ± SEM.
Fig. 2.
(A) The effect of i.p. injection of the p110δ inhibitor [IC87114] (0.1 mg/kg) 30 min before amphetamine injection (0.75 mg/kg or 1.5 mg/kg) on locomotion in the mouse showed a significant interaction with amphetamine dose and time [treatment × dose × time (F(14, 308) = 3.04; P = 0.0002): solid circle, IC87114 pretreatment, 1.5 mg/kg amphetamine, n = 7; solid triangle, vehicle pretreatment, 1.5 mg/kg amphetamine, n = 7; open triangle, vehicle pretreatment, 0.75 mg/kg amphetamine, n = 7; open circle, IC87114 pretreatment, 0.75 mg/kg amphetamine, n = 7]. Posthoc tests revealed that pretreatment with IC87114 abolished the hyperlocomotor effects of 1.5 mg/kg amphetamine (*P < 0.05 vs. IC87114 pretreatment; #P < 0.05, 1.5 mg/kg amphetamine vs. 0.75 mg/kg amphetamine). No effects of IC87114 were observed on normal baseline locomotor activity (Inset: solid triangle, IC87114, n = 19; open circle, vehicle, n = 18). (B) Acute IC87114 treatment in mouse (0.1 mg/kg) increases phosphorylation of AKT at Thr308 (*P ≤ 0.05). Striatum, n = 4 per group. (C) Effect of pretreatment with IC87114 (0.1 mg/kg) 30 min before apomorphine injection on PPI in the NVHL rat model showed a highly significant interaction with lesion status [Treatment × lesion: F(1, 112) = 13.81, P < 0.00001]. Posthoc tests revealed significant improvement of PPI in NVHL rats treated with IC87114 compared with vehicle [F(1, 56) = 7.3, P < 0.009] and no significant effect of IC87114 on sham-operated rats [F(1, 55) = 7.3, P = 0.085]. Main effects of lesion status (F = 9.33; P = 0.003) and prepulse intensity (F = 20.78; P < 0.00001) were also observed on PPI, whereby PPI progressively increased with higher prepulse intensities and NVHL rats had reduced PPI compared with controls. n = 9–11 rats per group. Mean ± SEM.
Comment in
- Finding a druggable target for schizophrenia.
Rico B. Rico B. Proc Natl Acad Sci U S A. 2012 Jul 24;109(30):11902-3. doi: 10.1073/pnas.1209389109. Epub 2012 Jul 9. Proc Natl Acad Sci U S A. 2012. PMID: 22778429 Free PMC article. No abstract available.
Similar articles
- Behavioral, Neurophysiological, and Synaptic Impairment in a Transgenic Neuregulin1 (NRG1-IV) Murine Schizophrenia Model.
Papaleo F, Yang F, Paterson C, Palumbo S, Carr GV, Wang Y, Floyd K, Huang W, Thomas CJ, Chen J, Weinberger DR, Law AJ. Papaleo F, et al. J Neurosci. 2016 Apr 27;36(17):4859-75. doi: 10.1523/JNEUROSCI.4632-15.2016. J Neurosci. 2016. PMID: 27122041 Free PMC article. - Finding a druggable target for schizophrenia.
Rico B. Rico B. Proc Natl Acad Sci U S A. 2012 Jul 24;109(30):11902-3. doi: 10.1073/pnas.1209389109. Epub 2012 Jul 9. Proc Natl Acad Sci U S A. 2012. PMID: 22778429 Free PMC article. No abstract available. - Neuregulin-1 signalling and antipsychotic treatment: potential therapeutic targets in a schizophrenia candidate signalling pathway.
Deng C, Pan B, Engel M, Huang XF. Deng C, et al. Psychopharmacology (Berl). 2013 Mar;226(2):201-15. doi: 10.1007/s00213-013-3003-2. Epub 2013 Feb 7. Psychopharmacology (Berl). 2013. PMID: 23389757 Review. - Differential effects of short- and long-term antipsychotic treatment on the expression of neuregulin-1 and ErbB4 receptors in the rat brain.
Deng C, Pan B, Hu CH, Han M, Huang XF. Deng C, et al. Psychiatry Res. 2015 Feb 28;225(3):347-54. doi: 10.1016/j.psychres.2014.12.014. Epub 2014 Dec 19. Psychiatry Res. 2015. PMID: 25576368 - Neuregulin 1 in neural development, synaptic plasticity and schizophrenia.
Mei L, Xiong WC. Mei L, et al. Nat Rev Neurosci. 2008 Jun;9(6):437-52. doi: 10.1038/nrn2392. Epub 2008 May 14. Nat Rev Neurosci. 2008. PMID: 18478032 Free PMC article. Review.
Cited by
- Gene expression changes in Brodmann's Area 46 differentiate epidermal growth factor and immune system interactions in schizophrenia and mood disorders.
Ketharanathan T, Pereira A, Sundram S. Ketharanathan T, et al. Schizophrenia (Heidelb). 2024 Sep 6;10(1):76. doi: 10.1038/s41537-024-00488-8. Schizophrenia (Heidelb). 2024. PMID: 39242583 Free PMC article. - Nuclear Softness Promotes the Metastatic Potential of Large-Nucleated Colorectal Cancer Cells via the ErbB4-Akt1-Lamin A/C Signaling Pathway.
Li Y, Li Q, Mu L, Hu Y, Yan C, Zhao H, Mi Y, Li X, Tao D, Qin J. Li Y, et al. Int J Biol Sci. 2024 Apr 29;20(7):2748-2762. doi: 10.7150/ijbs.89481. eCollection 2024. Int J Biol Sci. 2024. PMID: 38725859 Free PMC article. - Delineating mechanisms underlying parvalbumin neuron impairment in different neurological and neurodegenerative disorders: the emerging role of mitochondrial dysfunction.
Olkhova EA, Smith LA, Dennis BH, Ng YS, LeBeau FEN, Gorman GS. Olkhova EA, et al. Biochem Soc Trans. 2024 Apr 24;52(2):553-565. doi: 10.1042/BST20230191. Biochem Soc Trans. 2024. PMID: 38563502 Free PMC article. Review. - Epigenetic profile of the immune system associated with symptom severity and treatment response in schizophrenia.
Tang Y, Tan Y, Palaniyappan L, Yao Y, Luo Q, Li Y. Tang Y, et al. J Psychiatry Neurosci. 2024 Feb 15;49(1):E45-E58. doi: 10.1503/jpn.230099. Print 2024 Jan-Feb. J Psychiatry Neurosci. 2024. PMID: 38359932 Free PMC article. - Construction of a Diagnostic Model and a lncRNA-Associated ceRNA Network Based on Apoptosis-Related Genes for Schizophrenia.
Ma ZL, Wang RL, Meng L. Ma ZL, et al. Behav Neurol. 2023 Jun 20;2023:7017106. doi: 10.1155/2023/7017106. eCollection 2023. Behav Neurol. 2023. PMID: 37383091 Free PMC article.
References
- Harrison PJ, Weinberger DR. Schizophrenia genes, gene expression, and neuropathology: On the matter of their convergence. Mol Psychiatry. 2005;10:40–68, 5. - PubMed
- Harrison PJ, Law AJ. Neuregulin 1 and schizophrenia: Genetics, gene expression, and neurobiology. Biol Psychiatry. 2006;60:132–140. - PubMed
- Allen NC, et al. Systematic meta-analyses and field synopsis of genetic association studies in schizophrenia: The SzGene database. Nat Genet. 2008;40:827–834. - PubMed
- Silberberg G, Darvasi A, Pinkas-Kramarski R, Navon R. The involvement of ErbB4 with schizophrenia: Association and expression studies. Am J Med Genet B Neuropsychiatr Genet. 2006;141B:142–148. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases
Research Materials
Miscellaneous